[1]
Bhattacharyya N. Survival and prognosis in Hürthle cell carcinoma of the thyroid gland. Archives of otolaryngology--head & neck surgery. 2003 Feb:129(2):207-10
[PubMed PMID: 12578450]
[2]
Zhou X, Zheng Z, Chen C, Zhao B, Cao H, Li T, Liu X, Wang W, Li Y. Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study. BMC cancer. 2020 May 12:20(1):407. doi: 10.1186/s12885-020-06915-0. Epub 2020 May 12
[PubMed PMID: 32398118]
[3]
Hedinger C, Williams ED, Sobin LH. The WHO histological classification of thyroid tumors: a commentary on the second edition. Cancer. 1989 Mar 1:63(5):908-11
[PubMed PMID: 2914297]
Level 3 (low-level) evidence
[4]
Barnabei A, Ferretti E, Baldelli R, Procaccini A, Spriano G, Appetecchia M. Hurthle cell tumours of the thyroid. Personal experience and review of the literature. Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale. 2009 Dec:29(6):305-11
[PubMed PMID: 20463834]
[5]
Erickson LA, Jalal SM, Goellner JR, Law ME, Harwood A, Jin L, Roche PC, Lloyd RV. Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization. The American journal of surgical pathology. 2001 Jul:25(7):911-7
[PubMed PMID: 11420462]
[6]
Cibas ES, Ali SZ. The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid : official journal of the American Thyroid Association. 2017 Nov:27(11):1341-1346. doi: 10.1089/thy.2017.0500. Epub
[PubMed PMID: 29091573]
[7]
Yip L, Wharry LI, Armstrong MJ, Silbermann A, McCoy KL, Stang MT, Ohori NP, LeBeau SO, Coyne C, Nikiforova MN, Bauman JE, Johnson JT, Tublin ME, Hodak SP, Nikiforov YE, Carty SE. A clinical algorithm for fine-needle aspiration molecular testing effectively guides the appropriate extent of initial thyroidectomy. Annals of surgery. 2014 Jul:260(1):163-8. doi: 10.1097/SLA.0000000000000215. Epub
[PubMed PMID: 24901361]
[8]
Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet (London, England). 2013 Mar 23:381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9. Epub 2013 Mar 22
[PubMed PMID: 23668556]
[9]
Hodak SP, Rosenthal DS, American Thyroid Association Clinical Affairs Committee. Information for clinicians: commercially available molecular diagnosis testing in the evaluation of thyroid nodule fine-needle aspiration specimens. Thyroid : official journal of the American Thyroid Association. 2013 Feb:23(2):131-4. doi: 10.1089/thy.2012.0320. Epub 2012 Nov 27
[PubMed PMID: 22984796]
[10]
Kuo EJ, Roman SA, Sosa JA. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: a population level study of 22,738 patients. Surgery. 2013 Dec:154(6):1246-53; discussion 1253-4. doi: 10.1016/j.surg.2013.04.033. Epub 2013 Aug 28
[PubMed PMID: 23993409]
[11]
McHenry CR, Sandoval BA. Management of follicular and Hürthle cell neoplasms of the thyroid gland. Surgical oncology clinics of North America. 1998 Oct:7(4):893-910
[PubMed PMID: 9735140]
[12]
Sanders LE,Silverman M, Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. Surgery. 1998 Dec;
[PubMed PMID: 9854570]
[13]
McDonald MP, Sanders LE, Silverman ML, Chan HS, Buyske J. Hürthle cell carcinoma of the thyroid gland: prognostic factors and results of surgical treatment. Surgery. 1996 Dec:120(6):1000-4; discussion 1004-5
[PubMed PMID: 8957486]
[14]
Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer control : journal of the Moffitt Cancer Center. 2011 Apr:18(2):89-95
[PubMed PMID: 21451451]
[15]
Romesser PB, Sherman EJ, Shaha AR, Lian M, Wong RJ, Sabra M, Rao SS, Fagin JA, Tuttle RM, Lee NY. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. Journal of surgical oncology. 2014 Sep:110(4):375-82. doi: 10.1002/jso.23656. Epub 2014 Jun 24
[PubMed PMID: 24961938]
[16]
Servagi Vernat S, Khalifa J, Sun XS, Kammerer E, Blais E, Faivre JC, Sio TT, Pan J, Qiu H, Bar-Sela G, Simon JM, Salleron J, Thariat J. 10-Year Locoregional Control with Postoperative External Beam Radiotherapy in Patients with Locally Advanced High-Risk Non-Anaplastic Thyroid Carcinoma De Novo or at Relapse, a Propensity Score Analysis. Cancers. 2019 Jun 19:11(6):. doi: 10.3390/cancers11060849. Epub 2019 Jun 19
[PubMed PMID: 31248183]
Level 2 (mid-level) evidence
[17]
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. The New England journal of medicine. 2015 Feb 12:372(7):621-30. doi: 10.1056/NEJMoa1406470. Epub
[PubMed PMID: 25671254]
[18]
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, DECISION investigators. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England). 2014 Jul 26:384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24
[PubMed PMID: 24768112]
Level 1 (high-level) evidence
[19]
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. The New England journal of medicine. 2018 Feb 22:378(8):731-739. doi: 10.1056/NEJMoa1714448. Epub
[PubMed PMID: 29466156]
[20]
Drilon A, Siena S, Dziadziuszko R, Barlesi F, Krebs MG, Shaw AT, de Braud F, Rolfo C, Ahn MJ, Wolf J, Seto T, Cho BC, Patel MR, Chiu CH, John T, Goto K, Karapetis CS, Arkenau HT, Kim SW, Ohe Y, Li YC, Chae YK, Chung CH, Otterson GA, Murakami H, Lin CC, Tan DSW, Prenen H, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Doebele RC, trial investigators. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. The Lancet. Oncology. 2020 Feb:21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11
[PubMed PMID: 31838015]
[21]
Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, Worden F, Brose M, Patel J, Leboulleux S, Godbert Y, Barlesi F, Morris JC, Owonikoko TK, Tan DSW, Gautschi O, Weiss J, de la Fouchardière C, Burkard ME, Laskin J, Taylor MH, Kroiss M, Medioni J, Goldman JW, Bauer TM, Levy B, Zhu VW, Lakhani N, Moreno V, Ebata K, Nguyen M, Heirich D, Zhu EY, Huang X, Yang L, Kherani J, Rothenberg SM, Drilon A, Subbiah V, Shah MH, Cabanillas ME. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. The New England journal of medicine. 2020 Aug 27:383(9):825-835. doi: 10.1056/NEJMoa2005651. Epub
[PubMed PMID: 32846061]
[22]
Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V, Rolfo C. RET fusions in solid tumors. Cancer treatment reviews. 2019 Dec:81():101911. doi: 10.1016/j.ctrv.2019.101911. Epub 2019 Oct 30
[PubMed PMID: 31715421]
[23]
Drilon A, Oxnard GR, Tan DSW, Loong HHF, Johnson M, Gainor J, McCoach CE, Gautschi O, Besse B, Cho BC, Peled N, Weiss J, Kim YJ, Ohe Y, Nishio M, Park K, Patel J, Seto T, Sakamoto T, Rosen E, Shah MH, Barlesi F, Cassier PA, Bazhenova L, De Braud F, Garralda E, Velcheti V, Satouchi M, Ohashi K, Pennell NA, Reckamp KL, Dy GK, Wolf J, Solomon B, Falchook G, Ebata K, Nguyen M, Nair B, Zhu EY, Yang L, Huang X, Olek E, Rothenberg SM, Goto K, Subbiah V. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. The New England journal of medicine. 2020 Aug 27:383(9):813-824. doi: 10.1056/NEJMoa2005653. Epub
[PubMed PMID: 32846060]
[24]
Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, Geva R, Gottfried M, Penel N, Hansen AR, Piha-Paul SA, Doi T, Gao B, Chung HC, Lopez-Martin J, Bang YJ, Frommer RS, Shah M, Ghori R, Joe AK, Pruitt SK, Diaz LA Jr. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2020 Jan 1:38(1):1-10. doi: 10.1200/JCO.19.02105. Epub 2019 Nov 4
[PubMed PMID: 31682550]
[25]
Shaha AR, Ferlito A, Rinaldo A. Distant metastases from thyroid and parathyroid cancer. ORL; journal for oto-rhino-laryngology and its related specialties. 2001 Jul-Aug:63(4):243-9
[PubMed PMID: 11408821]
[26]
Carcangiu ML, Bianchi S, Savino D, Voynick IM, Rosai J. Follicular Hurthle cell tumors of the thyroid gland. Cancer. 1991 Nov 1:68(9):1944-53
[PubMed PMID: 1913544]
[27]
Kushchayeva Y, Duh QY, Kebebew E, Clark OH. Prognostic indications for Hürthle cell cancer. World journal of surgery. 2004 Dec:28(12):1266-70
[PubMed PMID: 15517492]
[28]
Lopez-Penabad L, Chiu AC, Hoff AO, Schultz P, Gaztambide S, Ordoñez NG, Sherman SI. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid. Cancer. 2003 Mar 1:97(5):1186-94
[PubMed PMID: 12599224]
[29]
Zhang YW, Greenblatt DY, Repplinger D, Bargren A, Adler JT, Sippel RS, Chen H. Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Annals of surgical oncology. 2008 Oct:15(10):2842-6. doi: 10.1245/s10434-008-0079-8. Epub 2008 Jul 30
[PubMed PMID: 18665423]